Sanofi-Aventis US has expanded its agreement with Ingenuity Systems for access to the company’s pathways analysis software, a web-delivered application used in drug discovery and development.
Ingenuity Pathways Analysis (IPA) enables researchers to model, analyze and understand the complex biological systems at the core of life science research. According to Ingenuity, IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally.
The software supports analysis of all high-throughput analysis platforms and is used in virtually all areas of drug discovery and development, from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
Sanofi-Aventis was one of the earliest adopters of Ingenuity technology and we are very pleased that we have been able to expand our relationship with this terrific team year after year, stated Peter DiLaura, Ingenuity’s vice president of sales and customer support.
